GlobeNewswire: Progenics Pharmaceuticals Inc. Contains the last 10 of 260 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T17:28:41ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/06/16/2049136/0/en/Progenics-Stockholders-Approve-Merger-with-Lantheus.html?f=22&fvtc=4&fvtv=12583Progenics Stockholders Approve Merger with Lantheus2020-06-16T20:05:00Z<![CDATA[NEW YORK, June 16, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) (“Progenics”), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, announced that at a special meeting of its stockholders held earlier today, Progenics’ stockholders voted to approve its proposed merger with Lantheus Holdings, Inc. (“Lantheus”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, by adopting the previously announced Amended and Restated Agreement and Plan of Merger, dated as of February 20, 2020 (the “Merger Agreement”), by and among Progenics, Lantheus and Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus (“Merger Sub”), pursuant to which Merger Sub will be merged with and into Progenics (the “merger”), with Progenics surviving the merger as a wholly-owned subsidiary of Lantheus.]]>https://www.globenewswire.com/news-release/2020/05/18/2034947/0/en/Progenics-to-Present-Results-from-the-Phase-3-CONDOR-Trial-of-PyL-18F-DCFPyL-in-Prostate-Cancer-at-the-American-Society-of-Clinical-Oncology-2020-Virtual-Scientific-Program.html?f=22&fvtc=4&fvtv=12583Progenics to Present Results from the Phase 3 CONDOR Trial of PyL™ (18F-DCFPyL) in Prostate Cancer at the American Society of Clinical Oncology 2020 Virtual Scientific Program2020-05-18T12:30:00Z<![CDATA[- Met Primary Endpoint with a Correct Localization Rate of 84.8–87.0% -- 63.9% Change in Disease Management Plan Based on PyL Imaging Results -- Planned NDA Submission On Track for Early Third Quarter 2020 -]]>https://www.globenewswire.com/news-release/2020/05/07/2029344/0/en/Progenics-Pharmaceuticals-Announces-First-Quarter-2020-Financial-Results-and-Business-Update.html?f=22&fvtc=4&fvtv=12583Progenics Pharmaceuticals Announces First Quarter 2020 Financial Results and Business Update2020-05-07T11:30:00Z<![CDATA[NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced financial results for the first quarter 2020.]]>https://www.globenewswire.com/news-release/2020/04/23/2020936/0/en/Progenics-Pharmaceuticals-Sets-First-Quarter-2020-Financial-Results-and-Business-Update-Call-for-May-7.html?f=22&fvtc=4&fvtv=12583Progenics Pharmaceuticals Sets First Quarter 2020 Financial Results and Business Update Call for May 72020-04-23T12:30:00Z<![CDATA[NEW YORK, April 23, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that it will host a conference call and webcast to review first quarter ended March 31, 2020 financial results on Thursday, May 7, 2020, at 8:30 a.m. ET.]]>https://www.globenewswire.com/news-release/2020/03/13/2000284/0/en/PROGENICS-PHARMACEUTICALS-ANNOUNCES-FOURTH-QUARTER-AND-FULL-YEAR-2019-FINANCIAL-RESULTS.html?f=22&fvtc=4&fvtv=12583PROGENICS PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS 2020-03-13T12:30:00Z<![CDATA[NEW YORK, March 13, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced financial results for the fourth quarter and full-year 2019.]]>https://www.globenewswire.com/news-release/2020/02/06/1981065/0/en/Progenics-Pharmaceuticals-Announces-Presentations-at-the-2020-American-Society-of-Clinical-Oncology-Genitourinary-Cancers-Symposium-Annual-Meeting-ASCO-GU.html?f=22&fvtc=4&fvtv=12583Progenics Pharmaceuticals Announces Presentations at the 2020 American Society of Clinical Oncology Genitourinary Cancers Symposium Annual Meeting (ASCO GU)2020-02-06T13:30:00Z<![CDATA[NEW YORK, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that three abstracts highlighting PyLTM (18F-DCFPyL), I-131 1095, and PSMA AI have been selected for oral and poster presentations at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium Annual Meeting (ASCO GU) , which will be held from February 13-15, 2020 in San Francisco, CA. Details on the presentations are included below.]]>https://www.globenewswire.com/news-release/2020/01/21/1973319/0/en/Progenics-Pharmaceuticals-Provides-Update-on-Reconstituted-Board-s-Ongoing-Strategic-Review.html?f=22&fvtc=4&fvtv=12583Progenics Pharmaceuticals Provides Update on Reconstituted Board’s Ongoing Strategic Review2020-01-21T21:15:00Z<![CDATA[NEW YORK, Jan. 21, 2020 (GLOBE NEWSWIRE) -- The Board of Directors of Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, issued the following letter to shareholders:]]>https://www.globenewswire.com/news-release/2020/01/16/1971475/0/en/Progenics-Pharmaceuticals-Announces-Presentation-at-the-2020-SNMMI-Mid-Winter-Meeting.html?f=22&fvtc=4&fvtv=12583Progenics Pharmaceuticals Announces Presentation at the 2020 SNMMI Mid-Winter Meeting2020-01-16T14:10:37Z<![CDATA[NEW YORK, Jan. 16, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that an abstract highlighting data from its PSMA AI program has been selected for a moderated poster presentation at the 2020 Society for Nuclear and Molecular Medicine (SNMMI) Mid-Winter Meeting, which will be held from January 23 – 25, 2020 in Tampa, FL.]]>https://www.globenewswire.com/news-release/2019/12/23/1964007/0/en/Progenics-Pharmaceuticals-Announces-Phase-3-CONDOR-Trial-of-PyL-in-Prostate-Cancer-Achieved-Primary-Endpoint.html?f=22&fvtc=4&fvtv=12583Progenics Pharmaceuticals Announces Phase 3 CONDOR Trial of PyL™ in Prostate Cancer Achieved Primary Endpoint2019-12-23T12:00:00Z<![CDATA[- Met Primary Endpoint With a Correct Localization Rate of 84.8–87.0%, Highlighting Strong Diagnostic Performance- Company Expects to Submit an NDA to the FDA in the Second Half of 2020- Conference Call at 8:00 AM Eastern Time]]>https://www.globenewswire.com/news-release/2019/12/22/1963825/0/en/Progenics-Pharmaceuticals-to-Announce-and-Host-a-Conference-Call-to-Discuss-Top-Line-Results-from-Phase-3-CONDOR-Trial-of-PyL-in-Prostate-Cancer-on-Monday-December-23rd.html?f=22&fvtc=4&fvtv=12583Progenics Pharmaceuticals to Announce and Host a Conference Call to Discuss Top Line Results from Phase 3 CONDOR Trial of PyL™ in Prostate Cancer on Monday, December 23rd2019-12-22T22:00:00Z<![CDATA[NEW YORK, Dec. 22, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that it will host a conference call to review the top line results from the Phase 3 CONDOR trial of PyL™ (18F-DCFPyL) in men with biochemical recurrence of prostate cancer on Monday, December 23, 2019, at 8:00 a.m. ET. The Company intends to issue a press release announcing the top line results of the CONDOR trial on the same day in advance of the conference call.]]>